As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
8 Analysts have issued a Carisma Therapeutics forecast:
8 Analysts have issued a Carisma Therapeutics forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 11 11 |
48%
48%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -44 -44 |
39%
39%
|
|
| EBIT (Operating Income) EBIT | -46 -46 |
39%
39%
|
|
| Net Profit | -49 -49 |
32%
32%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.
| Head office | United States |
| CEO | Steven Kelly |
| Employees | 46 |
| Founded | 2016 |
| Website | sesenbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


